Theravance Biopharma (TBPH) Accounts Payables (2013 - 2026)

Theravance Biopharma (TBPH) has reported Accounts Payables for 14 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables fell 54.32% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 54.32% YoY), while the FY2025 annual figure was $2.6 million, up 14.54% from the prior year.
• Accounts Payables slipped to $1.1 million in Q1 2026 per TBPH's latest filing, from $2.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $5.3 million in Q3 2022 and bottomed at $1.1 million in Q1 2026.
• Historically, Accounts Payables has averaged $2.2 million across 5 years, with a median of $1.7 million in 2024.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 77.9% — and 2023, when it surged 76.36%.
• Theravance Biopharma's Accounts Payables stood at $1.6 million in 2022, then dropped by 1.93% to $1.5 million in 2023, then jumped by 47.11% to $2.2 million in 2024, then climbed by 14.54% to $2.6 million in 2025, then slumped by 57.17% to $1.1 million in 2026.
• Business Quant data shows TBPH's Accounts Payables at $1.1 million in Q1 2026, $2.6 million in Q4 2025, and $2.2 million in Q3 2025.